Green Cross Obtains South Korean Approval For BioCryst Influenza Therapy Peramivir
This article was originally published in The Pink Sheet Daily
Executive Summary
The deal is part of a drive to secure anti-influenza options beyond Roche and GSK products in preparation for the next round of global influenza.